• Ratnam Kv


Moya moya syndrome is a specific chronic cerebrovascular occlusive disease first reported by Japanese surgeons in 1957. The disease moya moya, which is a Japanese mimetic word, gets its characteristic name due to the appearance of puff of smoke on relevant angiographs resultant from the tangle of tiny vessels in response to stenosis. This makes the blood to leak out of the arteries, causing pressure to the brain. It may cause ischemic attacks or cerebal infarction, which is more frequent in children than in adults. The highest peak is in childhood at less than 10 years of age. The disease causes constrictions primarily in the internal carotid artery, and often extends to the middle and anterior cerebral arteries, branches of the internal carotid artery inside the skull. When the internal carotid artery becomes completely blocked, the fine collateral circulation that it supplies is obliterated. The clinical features are strokes, recurrent transient ischemic attacks (TIAs), sensorimotor paralysis (numbness and paralysis of the extremities), convulsions and/or migraine -like headaches. Moreover, following a stroke, secondary bleeding may occur. Such bleeding, called hemorrhagic strokes.Treatment with perivascular sympathectomy and superior cervical ganglionectomy. Etiology of the disease is still unknown; however, multifactorial inheritance is considered possible because of a higher incidence of the disease in Japanese and Koreans and approximately 10% of familial occurrence among the Japanese. Recent genetic studies suggest some responsible genetic foci in chromosomes 3, 6 and 17.

Keywords: Moyamoya disease, Intracranial hemorrhage, Proteomics, Stenosis.


1. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 2008;79(8):900-4.
2. Kuroda S, Houkin K. Moyamoya disease: Current concepts and future perspectives. Lancet Neurol 2008;7(11):1056-66.
3. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG. Moyamoya
disease in Europe, past and present status. Clin Neurol Neurosurg 1997;99 Suppl 2:S58-60.
4. Kulakowska A, Kapica-Topczewska K, Borowik H, Drozdowski W. Moyamoya disease as a rare cause of ischaemic stroke – Case report. Pol Merkur Lekarski 2009;27(160):334-7.
5. Hallemeier C, Rich KM, Grubb RL Jr, Chicoine MR, Moran CJ,
Cross DT, et al. Epidemiological features of moyamoya disease in Japan: Findings from a nationwide survey. Stroke 2006;37(6):1490-6.
6. Gradzki J, Wróblewski T. Moyamoya syndrome (author’s transl). Pol Przegl Radiol Med Nukl 1980;44(4):273-7.
7. Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans. Stroke 2008;39(12):3193-200.
8. Shamim S, Kumar J, Jamalvi SW, Shaikh A. Moya Moya disease in a child. J Coll Physicians Surg Pak 2008;18(4):252-3.
9. Smith JL. Understanding and treating moyamoya disease in children. Neurosurg Focus 2009;26(4):E4.
10. Cerrato P, Grasso M, Lentini A, Destefanis E, Bosco G, Caprioli M,
et al. Atherosclerotic adult Moya-Moya disease in a patient with hyperhomocysteinaemia. Neurol Sci 2007;28(1):45-7.
11. Rabbani O, Bowen LE, Watson RT, Valenstein E, Okun MS. Alien limb syndrome and moya-moya disease. Mov Disord 2004;19(11):1317-20.
12. Fukui M. Current state of study on moyamoya disease in Japan. Surg Neurol 1997;47(2):138-43.
13. Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y. Radiological findings, clinical course, and outcome in asymptomatic moya moya disease: Results of multicenter survey in Japan. Stroke 2007;38:1430-5.
14. Wilmoth J, Skytthe A, Friou D, Jeune B. The oldest man ever? A case study of exceptional longevity. Gerontologist 1996;36(6):783-8.
15. Ishii K, Isono M, Kobayashi H, Kamida T. Temporal profile of
angiographical stages of moyamoya disease: When does moyamoya disease progress? Neurol Res 2003;25(4):405-10.
16. Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK. Progression of unilateral moyamoya disease: A clinical series.
Cerebrovasc Dis 2006;22(2-3):109-15.
17. Mandell DM, Han JS, Poublanc J, Crawley AP, Stainsby JA,
Fisher JA, et al. Mapping cerebrovascular reactivity using blood
oxygen level-dependent MRI in patients with arterial steno-occlusive disease: Comparison with arterial spin labeling MRI. Stroke
18. Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 2008;24(2):E17.
19. Yamamoto M, Aoyagi M, Tajima S, Wachi H, Fukai N, Matsushima Y, et al. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke 1997;28(9):1733-8.
20. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987;19 4 Suppl 5:19-25.
21. Hoshimaru M, Takahashi JA, Kikuchi H, Nagata I, Hatanaka M. Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: An immunohistochemical study. J Neurosurg 1991;75(2):267-70.
22. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem 1998;273(50):33103-6.
23. Schwartz MS, Scott RM. Moyamoya syndrome associated with cocaine abuse. Case report. Neurosurg Focus 1998;5(5):e7.
24. Akiyama K, Minakawa T, Tsuji Y, Isayama K. Arteriovenous
malformation associated with moyamoya disease: Case report. Surg Neurol 1994;41(6):468-71.
25. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-7.
26. Plasencia-Fernández E, Vázquez-López ME, Pulpeiro JR,
Molares-Rodríguez M, Morales-Redondo R. Transdural anastomosis in a juvenile form of moyamoya disease. Rev Neurol 1997;25(148):1939-41.
27. Hasuo K, Mihara F, Matsushima T. MRI and MR angiography in moyamoya disease. J Magn Reson Imaging 1998;8(4):762-6.
28. Taki W, Yonekawa Y, Kobayashi A, Ishikawa M, Kikuchi H, Nishizawa S, et al. Cerebral circulation and metabolism in adults moyamoya
disease – PET study. Acta Neurochir (Wien) 1989;100(3-4):150-4.
29. Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease.
Neuropathology 2000;20 Suppl: S61-4.
30. Kawaguchi S, Okuno S, Sakaki T. Effect of direct arterial bypass on the prevention of future stroke in patients with the hemorrhagic variety of moyamoya disease. J Neurosurg 2000;93(3):397-401.
31. Masuda J, Ogata J, Yamaguchi T, Mohr J, et al. Pathophysiology, Diagnosis, and Management. 4 ed. New York: Churchill Livingstone; 2004. p. 603-18.
th 32. Mesiwala AH, Sviri G, Fatemi N, Britz GW, Newell DW. Long-term outcome of superficial temporal artery-middle cerebral artery bypass for patients with moyamoya disease in the US. Neurosurg Focus 2008;24(2):E15.
33. Miyamoto S; Japan Adult Moyamoya Trial Group. Study design for a prospective randomized trial of extracranial-intracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset – The Japan Adult Moyamoya Trial Group. Neurol Med Chir (Tokyo) 2004;44(4):218-9.
34. Okada Y, Shima T, Nishida M, Yamane K, Yamada T, Yamanaka C. Effectiveness of superficial temporal artery-middle cerebral artery anastomosis in adult moyamoya disease: Cerebral hemodynamics and clinical course in ischemic and hemorrhagic varieties. Stroke 1998;29(3):625-630.
35. Reis CV, Safavi-Abbasi S, Zabramski JM, Gusmão SN, Spetzler RF, Preul MC. The history of neurosurgical procedures for moyamoya disease. Neurosurg Focus 2006;20(6):E7.
36. Suyama K, Yoshida K, Takahata H, Toda K, Baba H, Ishikawa Y, et al. Pediatric moyamoya disease presenting with intracerebral hemorrhage - Report of three cases and review of the literature. Clin Neurol Neurosurg 2008;110(3):270-5.
37. Vilela MD, Newell DW. Superficial temporal artery to middle
cerebral artery bypass: Past, present, and future. Neurosurg Focus 2008;24(2):E2.
38. Wanifuchi H, Takeshita M, Izawa M, Aoki N, Kagawa M. Management
of adult moyamoya disease. Neurol Med Chir (Tokyo) 1993;33(5):300-5.
504 Views | 404 Downloads
How to Cite
KVNR, A., and R. Kv. “MOYA MOYA DISEASE- A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 4, Apr. 2017, pp. 14-20, doi:10.22159/ajpcr.2017.v10i4.13453.
Review Article(s)